Epidemiology and therapies for metastatic sarcoma

References

• SiegelRNaishadhamDJemalACancer statistics, 2012CA Cancer J Clin2012621102922237781
   PubMed Web of Science ®Google Scholar
• FletcherCDMKrishnan UnniKMertensFWorld Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Soft Tissue and BoneLyonIRAC Press200211298
   Google Scholar
• HowladerNNooneAMKrapchoMSEER Cancer Statistics Review, 1975–2009 (Vintage 2009 Populations)Bethesda, MDNational Cancer Institute2012 Available from: http://seer.cancer.gov/csr/1975_2009_pops09/Accessed Dec 11, 2012
   Google Scholar
• BrulandOSHoifodtHHallKSSmelandSFodstadOBone marrow micrometastases studied by an immunomagnetic isolation procedure in extremity localized non-metastatic osteosarcoma patientsCancer Treat Res200915250951520213412
   PubMedGoogle Scholar
• DuboisSGEplingCLTeagueJMatthayKKSinclairEFlow cytometric detection of Ewing sarcoma cells in peripheral blood and bone marrowPediatr Blood Cancer2010541131819711435
   PubMed Web of Science ®Google Scholar
• DuBoisSGStempakDWuBCirculating endothelial cells and circulating endothelial precursor cells in patients with osteosarcomaPediatr Blood Cancer201258218118421319292
   PubMed Web of Science ®Google Scholar
• GallegoSLlortARomaJSabadoCGrosLde ToledoJSDetection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assayJ Cancer Res Clin Oncol2006132635636216435141
   PubMed Web of Science ®Google Scholar
• HoshinoMOgoseAKawashimaHMolecular analyses of cell origin and detection of circulating tumor cells in the peripheral blood in alveolar soft part sarcomaCancer Genet Cytogenet20091902758019380023
   PubMedGoogle Scholar
• PennacchioliETostiGBarberisMSarcoma spreads primarily through the vascular system: are there biomarkers associated with vascular spread?Clin Exp Metastasis201229775777322699363
   PubMed Web of Science ®Google Scholar
• Surveillance Research Program NCIFast Stats: An Interactive Tool for Access to SEER Cancer Statistics Available from: http://profiles.wizfolio.com/LayYiFei/publications/26760/178397/Accessed April 8, 2013
   Google Scholar
• Berrington de GonzalezAKutsenkoARajaramanPSarcoma risk after radiation exposureClin Sarcoma Res2012211823036235
   PubMedGoogle Scholar
• HawkinsMMWilsonLMBurtonHSRadiotherapy, alkylating agents, and risk of bone cancer after childhood cancerJ Natl Cancer Inst19968852702788614005
   PubMedGoogle Scholar
• KarlssonPHolmbergESamuelssonAJohanssonKAWallgrenASoft tissue sarcoma after treatment for breast cancer – a Swedish population-based studyEur J Cancer199834132068207510070313
   PubMed Web of Science ®Google Scholar
• MavrogenisAFPalaEGuerraGRuggieriPPost-radiation sarcomas. Clinical outcome of 52 PatientsJournal of surgical oncology2012105657057622012601
   PubMed Web of Science ®Google Scholar
• WickerhamDLFisherBWolmarkNAssociation of tamoxifen and uterine sarcomaJ Clin Oncol200220112758276012039943
   PubMed Web of Science ®Google Scholar
• da SilvaSRde OliveiraDEHIV, EBV and KSHV: viral cooperation in the pathogenesis of human malignanciesCancer Lett2011305217518521402436
   PubMed Web of Science ®Google Scholar
• BhatiaKShielsMSBergAEngelsEASarcomas other than Kaposi sarcoma occurring in immunodeficiency: interpretations from a systematic literature reviewCurr Opin Oncol201224553754622729152
   PubMed Web of Science ®Google Scholar
• BalarajanRAchesonEDSoft tissue sarcomas in agriculture and forestry workersJ Epidemiol Community Health19843821131166747508
   PubMed Web of Science ®Google Scholar
• SerrainoDFranceschiSLa VecchiaCCarboneAOccupation and soft-tissue sarcoma in northeastern ItalyCancer Causes Control19923125301536910
   PubMed Web of Science ®Google Scholar
• WingrenGFredriksonMBrageHNNordenskjoldBAxelsonOSoft tissue sarcoma and occupational exposuresCancer19906648068112386907
   PubMed Web of Science ®Google Scholar
• MerlettiFRichiardiLBertoniFOccupational factors and risk of adult bone sarcomas: a multicentric case-control study in EuropeInt J Cancer2006118372172716108052
   PubMed Web of Science ®Google Scholar
• PukkalaEMartinsenJILyngeEOccupation and cancer – follow-up of 15 million people in five Nordic countriesActa Oncol200948564679019925375
   PubMed Web of Science ®Google Scholar
• ErikssonMHardellLAdamiHOExposure to dioxins as a risk factor for soft tissue sarcoma: a population-based case-control studyJ Natl Cancer Inst19908264864902313720
   PubMedGoogle Scholar
• HoppinJATolbertPEHerrickRFOccupational chlorophenol exposure and soft tissue sarcoma risk among men aged 30–60 yearsAm J Epidemiol199814876937039778176
   PubMed Web of Science ®Google Scholar
• KogevinasMKauppinenTWinkelmannRSoft tissue sarcoma and non-Hodgkin’s lymphoma in workers exposed to phenoxy herbicides, chlorophenols, and dioxins: two nested case-control studiesEpidemiology1995643964027548348
   PubMed Web of Science ®Google Scholar
• HardellLErikssonMThe association between soft tissue sarcomas and exposure to phenoxyacetic acids. A new case-referent studyCancer19886236526563390800
   PubMed Web of Science ®Google Scholar
• SmithJGChristophersAJPhenoxy herbicides and chlorophenols: a case control study on soft tissue sarcoma and malignant lymphomaBr J Cancer19926534424481558802
   PubMed Web of Science ®Google Scholar
• WoodsJSPolissarLSeversonRKHeuserLSKulanderBGSoft tissue sarcoma and non-Hodgkin’s lymphoma in relation to phenoxyherbicide and chlorinated phenol exposure in western WashingtonJ Natl Cancer Inst19877858999103471999
   PubMed Web of Science ®Google Scholar
• OgnjanovicSMartelGManivelCOlivierMLangerEHainautPLow Prevalence of TP53 Mutations and MDM2 Amplifications in Pediatric RhabdomyosarcomaSarcoma2012201249208622550420
   PubMedGoogle Scholar
• HansenMFKoufosAGallieBLOsteosarcoma and retinoblastoma: a shared chromosomal mechanism revealing recessive predispositionProc Natl Acad Sci USA19858218621662202994066
   PubMed Web of Science ®Google Scholar
• HsuJJKamath-LoebASGlickEWerner syndrome gene variants in human sarcomasMol Carcinog201049216617419824023
   PubMed Web of Science ®Google Scholar
• HansenMFSetonMMerchantAOsteosarcoma in Paget’s disease of boneJ Bone Miner Res200621Suppl 2P58P6317229010
   PubMed Web of Science ®Google Scholar
• OttavianiGJaffeNThe etiology of osteosarcomaCancer Treat Res2009152153220213384
   PubMedGoogle Scholar
• SavageSAMirabelloLUsing epidemiology and genomics to understand osteosarcoma etiologySarcoma2011201154815121437228
   PubMedGoogle Scholar
• ClintonCGazdaHTDiamond-blackfan anemiaPagonRABirdTDDolanCRStephensKAdamMPGeneReviewsSeattle WAUniversity of Washington, Seattle1993
   Google Scholar
• FiorettiFTavaniAGallusSNegriEFranceschiSLa VecchiaCMenstrual and reproductive factors and risk of soft tissue sarcomasCancer200088478678910679647
   PubMed Web of Science ®Google Scholar
• AnfinsenKPDevesaSSBrayFAge-period-cohort analysis of primary bone cancer incidence rates in the United States (1976–2005)Cancer Epidemiol Biomarkers Prev20112081770177721724855
   PubMed Web of Science ®Google Scholar
• WinnDMLiFPRobisonLLMulvihillJJDaigleAEFraumeniJFJrA case-control study of the etiology of Ewing’s sarcomaCancer Epidemiol Biomarkers Prev1992175255321302564
   PubMed Web of Science ®Google Scholar
• GruffermanSWangHHDeLongERKimmSYDelzellESFallettaJMEnvironmental factors in the etiology of rhabdomyosarcoma in childhoodJ Natl Cancer Inst19826811071136948120
   PubMed Web of Science ®Google Scholar
• MirabelloLPfeifferRMurphyGHeight at diagnosis and birth-weight as risk factors for osteosarcomaCancer Causes Control201122689990821465145
   PubMed Web of Science ®Google Scholar
• SpectorLGPuumalaSECarozzaSECancer risk among children with very low birth weightsPediatrics200912419610419564288
   PubMed Web of Science ®Google Scholar
• OgnjanovicSCarozzaSEChowEJBirth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtypeBri J Cancer20101021227231
   Web of Science ®Google Scholar
• Von BehrenJSpectorLGMuellerBABirth order and risk of childhood cancer: a pooled analysis from five US StatesInt J Cancer2011128112709271620715170
   PubMed Web of Science ®Google Scholar
• BurninghamZHashibeMSpectorLSchiffmanJDThe epidemiology of sarcomaClin Sarcoma Res2012211423036164
   PubMedGoogle Scholar
• ArndtCACristWMCommon musculoskeletal tumors of childhood and adolescenceN Engl J Med1999341534235210423470
   PubMed Web of Science ®Google Scholar
• MalempatiSHawkinsDSRhabdomyosarcoma: review of the Children’s Oncology Group (COG) Soft-Tissue Sarcoma Committee experience and rationale for current COG studiesPediatr Blood Cancer201259151022378628
   PubMed Web of Science ®Google Scholar
• CristWGehanEARagabAHThe Third Intergroup Rhabdomyosarcoma StudyJ Clin Oncol19951336106307884423
   PubMed Web of Science ®Google Scholar
• MaurerHMBeltangadyMGehanEAThe Intergroup Rhabdomyosarcoma Study-I. A final reportCancer19886122092203275486
   PubMed Web of Science ®Google Scholar
• MaurerHMGehanEABeltangadyMThe Intergroup Rhabdomyosarcoma Study-IICancer1993715190419228448756
   PubMed Web of Science ®Google Scholar
• DantonelloTMInt-VeenCWinklerPInitial patient characteristics can predict pattern and risk of relapse in localized rhabdomyosarcomaJ Clin Oncol200826340641318202417
   PubMed Web of Science ®Google Scholar
• BrenemanJCLydenEPappoASPrognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma – a report from the Intergroup Rhabdomyosarcoma Study IVJ Clin Oncol2003211788412506174
   PubMed Web of Science ®Google Scholar
• OberlinOReyALydenEPrognostic factors in metastatic rhabdomyosarcomas: results of a pooled analysis from United States and European cooperative groupsJ Clin Oncol200826142384238918467730
   PubMed Web of Science ®Google Scholar
• RodebergDAGarcia-HenriquezNLydenERPrognostic significance and tumor biology of regional lymph node disease in patients with rhabdomyosarcoma: a report from the Children’s Oncology GroupJ Clin Oncol201129101304131121357792
   PubMed Web of Science ®Google Scholar
• WeigelBLydenEAndersonJREarly results from Children’s Oncology Group (COG) ARST0431: intensive multidrug therapy for patients with metastatic rhabdomyosarcoma (RMS). 2010 ASCO Annual MeetingJ Clin Oncol201028Suppl 15A-9503
   Web of Science ®Google Scholar
• PeinemannFKrogerNBartelCHigh-dose chemotherapy followed by autologous stem cell transplantation for metastatic rhabdomyosarcoma – a systematic reviewPloS One201162e1712721373200
   PubMed Web of Science ®Google Scholar
• WeigelBJBreitfeldPPHawkinsDCristWMBakerKSRole of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcomaJ Pediatr Hematol Oncol200123527227611464981
   PubMed Web of Science ®Google Scholar
• BenjaminRSPatelSRPediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapyCancer Treat Res200915235536320213401
   PubMedGoogle Scholar
• LinkMPGoorinAMMiserAWThe effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremityN Engl J Med198631425160016063520317
   PubMed Web of Science ®Google Scholar
• EilberFGiulianoAEckardtJPattersonKMoseleySGoodnightJAdjuvant chemotherapy for osteosarcoma: a randomized prospective trialJ Clin Oncol19875121263543236
   PubMed Web of Science ®Google Scholar
• KagerLZoubekAPotschgerUPrimary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocolsJ Clin Oncol200321102011201812743156
   PubMed Web of Science ®Google Scholar
• MeyersPAHellerGHealeyJHOsteogenic sarcoma with clinically detectable metastasis at initial presentationJ Clin Oncol19931134494538445419
   PubMed Web of Science ®Google Scholar
• BrandalPBjerkehagenBBrulandOSSkjeldalSBogsrudTVHallKSSynchronous and metachronous skeletal osteosarcomas: the Norwegian Radium Hospital experienceActa Oncol20094881165117219863225
   PubMed Web of Science ®Google Scholar
• ChouAJKleinermanESKrailoMDAddition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology GroupCancer2009115225339534819637348
   PubMed Web of Science ®Google Scholar
• MeyersPASchwartzCLKrailoMDOsteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology GroupJ Clin Oncol200826463363818235123
   PubMed Web of Science ®Google Scholar
• JanewayKABarkauskasDAKrailoMDOutcome for adolescent and young adult patients with osteosarcoma: a report from the Children’s Oncology GroupCancer2012118184597460522252521
   PubMed Web of Science ®Google Scholar
• AljubranAHGriffinAPintilieMBlacksteinMOsteosarcoma in adolescents and adults: survival analysis with and without lung metastasesAnn Oncol20092061136114119153114
   PubMed Web of Science ®Google Scholar
• HartingMTLallyKPAndrassyRJAge as a prognostic factor for patients with osteosarcoma: an analysis of 438 patientsJ Cancer Res Clin Oncol2010136456157019784847
   PubMed Web of Science ®Google Scholar
• EbbDMeyersPGrierHPhase II trial of trastuzumab in combination with cytotoxic chemotherapy for treatment of metastatic osteosarcoma with human epidermal growth factor receptor 2 overexpression: a report from the children’s oncology groupJ Clin Oncol201230202545255122665540
   PubMed Web of Science ®Google Scholar
• O’DayKGorlickRNovel therapeutic agents for osteosarcomaExpert Rev Anticancer Ther20099451152319374604
   PubMed Web of Science ®Google Scholar
• Kempf-BielackBBielackSSJurgensHOsteosarcoma relapse after combined modality therapy: an analysis of unselected patients in the Cooperative Osteosarcoma Study Group (COSS)J Clin Oncol200523355956815659502
   PubMed Web of Science ®Google Scholar
• GelderblomHJinksRCSydesMSurvival after recurrent osteosarcoma: data from 3 European Osteosarcoma Intergroup (EOI) randomized controlled trialsEur J Cancer201147689590221216138
   PubMed Web of Science ®Google Scholar
• LetourneauPAXiaoLHartingMTLocation of pulmonary metastasis in pediatric osteosarcoma is predictive of outcomeJ Pediatr Surg20114671333133721763830
   PubMed Web of Science ®Google Scholar
• BielackSSKempf-BielackBBranscheidDSecond and subsequent recurrences of osteosarcoma: presentation, treatment, and outcomes of 249 consecutive cooperative osteosarcoma study group patientsJ Clin Oncol200927455756519075282
   PubMed Web of Science ®Google Scholar
• NathanSSGorlickRBukataSTreatment algorithm for locally recurrent osteosarcoma based on local disease-free interval and the presence of lung metastasisCancer200610771607161616933325
   PubMed Web of Science ®Google Scholar
• ScholzRBKabischHWeberBRoserKDellingGWinklerKStudies of the RB1 gene and the p53 gene in human osteosarcomasPediatr Hematol Oncol1992921251371524989
   PubMed Web of Science ®Google Scholar
• ChoyEHornicekFMacConaillLHigh-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenesCancer2012118112905291422006429
   PubMed Web of Science ®Google Scholar
• StephensPJGreenmanCDFuBMassive genomic rearrangement acquired in a single catastrophic event during cancer developmentCell20111441274021215367
   PubMed Web of Science ®Google Scholar
• OkounevaTAzarenkoOWilsonLLittlefieldBAJordanMAInhibition of centromere dynamics by eribulin (E7389) during mitotic metaphaseMol Cancer Ther2008772003201118645010
   PubMed Web of Science ®Google Scholar
• Rodriguez-GalindoCNavidFLiuTBillupsCARaoBNKrasinMJPrognostic factors for local and distant control in Ewing sarcoma family of tumorsAnn Oncol200819481482017998282
   PubMed Web of Science ®Google Scholar
• CotterillSJAhrensSPaulussenMPrognostic factors in Ewing’s tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing’s Sarcoma Study GroupJ Clin Oncol200018173108311410963639
   PubMed Web of Science ®Google Scholar
• EsiashviliNGoodmanMMarcusRBJrChanges in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results dataJ Pediatr Hematol Oncol200830642543018525458
   PubMed Web of Science ®Google Scholar
• LadensteinRPotschgerULe DeleyMCPrimary disseminated multifocal Ewing sarcoma: results of the Euro-EWING 99 trialJ Clin Oncol201028203284329120547982
   PubMed Web of Science ®Google Scholar
• TapWDDemetriGBarnettePPhase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumorsJ Clin Oncol201230151849185622508822
   PubMed Web of Science ®Google Scholar
• OlmosDPostel-VinaySMolifeLRSafety, pharmacokinetics, and preliminary activity of the anti-IGF-1R antibody figitumumab (CP-751,871) in patients with sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort studyLancet Oncol201011212913520036194
   PubMed Web of Science ®Google Scholar
• MalempatiSWeigelBIngleAMPhase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children’s Oncology GroupJ Clin Oncol201230325626222184397
   PubMed Web of Science ®Google Scholar
• JuergensHDawNCGeoergerBPreliminary efficacy of the anti-insulin-like growth factor type 1 receptor antibody figitumumab in patients with refractory Ewing sarcomaJ Clin Oncol201129344534454022025154
   PubMed Web of Science ®Google Scholar
• PappoASPatelSRCrowleyJR1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration studyJ Clin Oncol201129344541454722025149
   PubMed Web of Science ®Google Scholar
• AtzoriFTaberneroJCervantesAA phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumorsClinical Cancer Res201117196304631221810918
   PubMed Web of Science ®Google Scholar
• GarnettMJEdelmanEJHeidornSJSystematic identification of genomic markers of drug sensitivity in cancer cellsNature2012483739157057522460902
   PubMed Web of Science ®Google Scholar
• SoldatenkovVAAlborAPatelBKDreszerRDritschiloANotarioVRegulation of the human poly(ADP-ribose) polymerase promoter by the ETS transcription factorOncogene199918273954396210435618
   PubMed Web of Science ®Google Scholar
• GroharPJWoldemichaelGMGriffinLBIdentification of an inhibitor of the EWS-FLI1 oncogenic transcription factor by high-throughput screeningJ Nat Cancer Inst20111031296297821653923
   PubMed Web of Science ®Google Scholar
• Barber-RotenbergJSSelvanathanSPKongYSingle enantiomer of YK-4-279 demonstrates specificity in targeting the oncogene EWS-FLI1Oncotarget20123217218222383402
   PubMedGoogle Scholar
• ErkizanHVKongYMerchantMA small molecule blocking oncogenic protein EWS-FLI1 interaction with RNA helicase A inhibits growth of Ewing’s sarcomaNat Med200915775075619584866
   PubMed Web of Science ®Google Scholar
• ErkizanHVScherLJGambleSENovel peptide binds EWS-FLI1 and reduces the oncogenic potential in Ewing tumorsCell Cycle201110193397340821926473
   PubMed Web of Science ®Google Scholar
• Garrido-LagunaIJankuFRidaforolimus in advanced sarcomas: a leap forward or missed opportunity?J Clin Oncol201230889289322291080
   PubMed Web of Science ®Google Scholar
• KofmanSPerliaCPEconomouSGMithramycin in the treatment of metastatic Ewing’s sarcomaCancer19733148898934267530
   PubMed Web of Science ®Google Scholar
• Al-RefaieWBAndtbackaRHEnsorJLymphadenectomy for isolated lymph node metastasis from extremity soft-tissue sarcomasCancer200811281821182618306370
   PubMed Web of Science ®Google Scholar
• MazeronJJSuitHDLymph nodes as sites of metastases from sarcomas of soft tissueCancer1987608180018083308055
   PubMed Web of Science ®Google Scholar
• CoindreJMTerrierPGuillouLPredictive value of grade for metastasis development in the main histologic types of adult soft tissue sarcomas: a study of 1240 patients from the French Federation of Cancer Centers Sarcoma GroupCancer200191101914192611346874
   PubMed Web of Science ®Google Scholar
• BleyerAChoiMFullerCDThomasCRJrWangSJRelative lack of conditional survival improvement in young adults with cancerSemin Oncol200936546046719835741
   PubMed Web of Science ®Google Scholar
• BleyerAMontelloMBuddTSaxmanSNational survival trends of young adults with sarcoma: lack of progress is associated with lack of clinical trial participationCancer200510391891189715795902
   PubMed Web of Science ®Google Scholar
• ZbukKSidebothamELBleyerALa QuagliaMPColorectal cancer in young adultsSemin Oncol200936543945019835739
   PubMed Web of Science ®Google Scholar
• AlbrittonKHEdenTAccess to carePediatr Blood Cancer200850Suppl 51094109818360836
   PubMed Web of Science ®Google Scholar
• ButowPPalmerSPaiAGoodenoughBLuckettTKingMReview of adherence-related issues in adolescents and young adults with cancerJ Clin Oncol201028324800480920212260
   PubMed Web of Science ®Google Scholar
• Dang-TanTTrottierHMeryLSDelays in diagnosis and treatment among children and adolescents with cancer in CanadaPediatr Blood Cancer200851446847418454472
   PubMed Web of Science ®Google Scholar
• Downs-CannerSShawPHA comparison of clinical trial enrollment between adolescent and young adult (AYA) oncology patients treated at affiliated adult and pediatric oncology centersJ Pediatr Hematol Oncol2009311292792919855302
   PubMed Web of Science ®Google Scholar
• FerrariAMontelloMBuddTBleyerAThe challenges of clinical trials for adolescents and young adults with cancerPediatr Blood Cancer200850Suppl 51101110418360838
   PubMed Web of Science ®Google Scholar
• ItalianoAMathoulin-PelissierSCesneALTrends in survival for patients with metastatic soft-tissue sarcomaCancer201111751049105420945333
   PubMed Web of Science ®Google Scholar
• PenelNGlabbekeMVMathoulin-PelissierSPerformance status is the most powerful risk factor for early death among patients with advanced soft tissue sarcoma: the European Organisation for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (STBSG) and French Sarcoma Group (FSG) studyBr J Cancer2011104101544155021505457
   PubMed Web of Science ®Google Scholar
• MericFHessKRVarmaDGRadiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomasCancer20029551120112612209699
   PubMed Web of Science ®Google Scholar
• KimSOttHCWrightCDPulmonary resection of metastatic sarcoma: prognostic factors associated with improved outcomesAnn Thorac Surg2011925:17801786 discussion1786178722051274
   PubMed Web of Science ®Google Scholar
• KonZMartinLResection for thoracic metastases from sarcomaOncology (Williston Park)201125121198120422229212
   PubMed Web of Science ®Google Scholar
• PredinaJDPucMMBergeyMRImproved survival after pulmonary metastasectomy for soft tissue sarcomaJ Thorac Oncol20116591391921750417
   PubMed Web of Science ®Google Scholar
• BenjaminRSWiernikPHBachurNRAdriamycin: a new effective agent in the therapy of disseminated sarcomasMed Pediatr Oncol19751163761232527
   PubMedGoogle Scholar
• DemetriGDEliasADResults of single-agent and combination chemotherapy for advanced soft tissue sarcomas. Implications for decision making in the clinicHematol Oncol Clin North Am1995947657857490240
   PubMed Web of Science ®Google Scholar
• EdmonsonJHRyanLMBlumRHRandomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomasJ Clin Oncol1993117126912758315424
   PubMed Web of Science ®Google Scholar
• VermaSYounusJStys-NormanDHaynesAEBlacksteinMIfosfamide-based combination chemotherapy in advanced soft-tissue sarcoma: a practice guidelineCurr Oncol200714414414817710206
   PubMedGoogle Scholar
• VermaSYounusJStys-NormanDHaynesAEBlacksteinMMeta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcomaCancer Treat Rev200834433934718313854
   PubMed Web of Science ®Google Scholar
• AndersonSEKeohanMLD’AdamoDRMakiRGA retrospective analysis of vinorelbine chemotherapy for patients with previously treated soft-tissue sarcomasSarcoma200620061594717496991
   PubMedGoogle Scholar
• AntmanKHRyanLEliasAShermanDGrierHEResponse to ifosfamide and mesna: 124 previously treated patients with metastatic or unresectable sarcomaJ Clin Oncol1989711261312491883
   PubMed Web of Science ®Google Scholar
• HensleyMLMakiRVenkatramanEGemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trialJ Clin Oncol200220122824283112065559
   PubMed Web of Science ®Google Scholar
• KutteschJFJrKrailoMDMaddenTJohansenMBleyerAPhase II evaluation of intravenous vinorelbine (Navelbine) in recurrent or refractory pediatric malignancies: a Children’s Oncology Group studyPediatr Blood Cancer200953459059319533657
   PubMed Web of Science ®Google Scholar
• LeuKMOstruszkaLJShewachDLaboratory and clinical evidence of synergistic cytotoxicity of sequential treatment with gemcitabine followed by docetaxel in the treatment of sarcomaJ Clin Oncol20042291706171215117993
   PubMed Web of Science ®Google Scholar
• MakiRGWathenJKPatelSRRandomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]J Clin Oncol200725192755276317602081
   PubMed Web of Science ®Google Scholar
• NielsenOSJudsonIvan HoeselQEffect of high-dose ifosfamide in advanced soft tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma GroupEur J Cancer2000361616710741296
   PubMed Web of Science ®Google Scholar
• van OosteromATMouridsenHTNielsenOSResults of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patientsEur J Cancer200238182397240612460784
   PubMed Web of Science ®Google Scholar
• Van GlabbekeMvan OosteromATOosterhuisJWPrognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens – a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group StudyJ Clin Oncol199917115015710458228
   PubMed Web of Science ®Google Scholar
• SkubitzKMD’AdamoDRSarcomaMayo Clin Proc200782111409143217976362
   PubMed Web of Science ®Google Scholar
• KaravasilisVSeddonBMAshleySAl-MuderisOFisherCJudsonISignificant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patientsCancer200811271585159118278813
   PubMed Web of Science ®Google Scholar
• SpuntSLHillDAMotosueAMClinical features and outcome of initially unresected nonmetastatic pediatric nonrhabdomyosarcoma soft tissue sarcomaJ Clin Oncol200220153225323512149295
   PubMed Web of Science ®Google Scholar
• SpuntSLPappoASChildhood nonrhabdomyosarcoma soft tissue sarcomas are not adult-type tumorsJ Clin Oncol20062412:19581959 author reply1959196016622276
   PubMed Web of Science ®Google Scholar
• SpuntSLPoquetteCAHurtYSPrognostic factors for children and adolescents with surgically resected nonrhabdomyosarcoma soft tissue sarcoma: an analysis of 121 patients treated at St Jude Children’s Research HospitalJ Clin Oncol199917123697370510577841
   PubMed Web of Science ®Google Scholar
• SpuntSLSkapekSXCoffinCMPediatric nonrhabdomyosarcoma soft tissue sarcomasOncologist200813666867818586922
   PubMed Web of Science ®Google Scholar
• van der GraafWTBlayJYChawlaSPPazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialLancet201237998291879188622595799
   PubMed Web of Science ®Google Scholar
• HerzogCEOverview of sarcomas in the adolescent and young adult populationJ Pediatr Hematol Oncol200527421521815838394
   PubMed Web of Science ®Google Scholar
• National Cancer InstituteSurveillance Epidemiology End Results Available from: http://seer.cancer.govAccessed Dec 11, 2012
   Google Scholar
• TunnPUAndreouDIllingHFleigeBDreselSSchlagPMSentinel node biopsy in synovial sarcomaEur J Surg Oncol200834670470717870276
   PubMed Web of Science ®Google Scholar
• FerrariAGronchiACasanovaMSynovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institutionCancer2004101362763415274077
   PubMed Web of Science ®Google Scholar
• LewisJJAntonescuCRLeungDHSynovial sarcoma: a multivariate analysis of prognostic factors in 112 patients with primary localized tumors of the extremityJ Clin Oncol200018102087209410811674
   PubMed Web of Science ®Google Scholar
• SpurrellELFisherCThomasJMJudsonIRPrognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden HospitalAnn Oncol200516343744415653701
   PubMed Web of Science ®Google Scholar
• ClarkJRocquesPJCrewAJIdentification of novel genes, SYT and SSX, involved in the t(X;18)(p11.2;q11.2) translocation found in human synovial sarcomaNat Genet1994745025087951320
   PubMed Web of Science ®Google Scholar
• FerrariADe SalvoGLOberlinOSynovial sarcoma in children and adolescents: a critical reappraisal of staging investigations in relation to the rate of metastatic involvement at diagnosisEur J Cancer20124891370137522322070
   PubMed Web of Science ®Google Scholar
• LadanyiMAntonescuCRLeungDHImpact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patientsCancer Res200262113514011782370
   PubMed Web of Science ®Google Scholar
• LeeSHChangMHBaekKKHigh-dose ifosfamide as second-or third-line chemotherapy in refractory bone and soft tissue sarcoma patientsOncology2011803–425726121734417
   PubMed Web of Science ®Google Scholar
• SleijferSRay-CoquardIPapaiZPazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)J Clin Oncol200927193126313219451427
   PubMed Web of Science ®Google Scholar
• RobbinsPFMorganRAFeldmanSATumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1J Clin Oncol201129791792421282551
   PubMed Web of Science ®Google Scholar
• HerbstRSEckhardtSGKurzrockRPhase I dose-escalation study of recombinant human Apo2L/TRAIL, a dual proapoptotic receptor agonist, in patients with advanced cancerJ Clin Oncol201028172839284620458040
   PubMed Web of Science ®Google Scholar
• FoxEAplencRBagatellRA phase 1 trial and pharmacokinetic study of cediranib, an orally bioavailable pan-vascular endothelial growth factor receptor inhibitor, in children and adolescents with refractory solid tumorsJ Clin Oncol201028355174518121060028
   PubMed Web of Science ®Google Scholar
• KamranSCHowardSAShinagareABMalignant peripheral nerve sheath tumors: Prognostic impact of rhabdomyoblastic differentiation (malignant triton tumors), neurofibromatosis 1status and locationEur J Surg Oncol2013391465223084090
   PubMed Web of Science ®Google Scholar
• KatzDLazarALevDMalignant peripheral nerve sheath tumour (MPNST): the clinical implications of cellular signalling pathwaysExpert Rev Mol Med200911e3019835664
   PubMed Web of Science ®Google Scholar
• FeldkampMMAngelovLGuhaANeurofibromatosis type 1 peripheral nerve tumors: aberrant activation of the Ras pathwaySurg Neurol199951221121810029430
   PubMedGoogle Scholar
• LegiusEMarchukDACollinsFSGloverTWSomatic deletion of the neurofibromatosis type 1 gene in a neurofibrosarcoma supports a tumour suppressor gene hypothesisNat Genet1993321221268499945
   PubMed Web of Science ®Google Scholar
• XuGFO’ConnellPViskochilDThe neurofibromatosis type 1 gene encodes a protein related to GAPCell19906235996082116237
   PubMed Web of Science ®Google Scholar
• EvansDGBaserMEMcGaughranJSharifSHowardEMoranAMalignant peripheral nerve sheath tumours in neurofibromatosis 1J Med Genet200239531131412011145
   PubMed Web of Science ®Google Scholar
• FerrariAMiceliRCasanovaMAdult-type soft tissue sarcomas in paediatric age: a nomogram-based prognostic comparison with adult sarcomaEur J Cancer200743182691269717977712
   PubMed Web of Science ®Google Scholar
• KattanMWLeungDHBrennanMFPostoperative nomogram for 12-year sarcoma-specific deathJ Clin Oncol200220379179611821462
   PubMed Web of Science ®Google Scholar
• TregliaGTaralliSBertagnaFUsefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with neurofibromatosis type 1: a systematic reviewRadiol Res Pract2012201243102922991664
   PubMedGoogle Scholar
• MeleanGHernandezAMValeroMCHernandez-ImazEMartinYHernandez-ChicoCMonozygotic twins with Neurofibromatosis type 1, concordant phenotype and synchronous development of MPNST and metastasisBMC Cancer20101040720687928
   PubMed Web of Science ®Google Scholar
• SawadaSFlorellSPurandareSMOtaMStephensKViskochilDIdentification of NF1 mutations in both alleles of a dermal neurofibromaNat Genet19961411101128782831
   PubMed Web of Science ®Google Scholar
• SerraEPuigSOteroDConfirmation of a double-hit model for the NF1 gene in benign neurofibromasAm J Hum Genet19976135125199326316
   PubMed Web of Science ®Google Scholar
• EckertJMByerSJClodfelder-MillerBJCarrollSLNeuregulin-1 beta and neuregulin-1 alpha differentially affect the migration and invasion of malignant peripheral nerve sheath tumor cellsGlia200957141501152019306381
   PubMed Web of Science ®Google Scholar
• MillerSJJessenWJMehtaTIntegrative genomic analyses of neurofibromatosis tumours identify SOX9 as a biomarker and survival geneEMBO Mol Med20091423624820049725
   PubMed Web of Science ®Google Scholar
• BremsHBeertEde RavelTLegiusEMechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1Lancet Oncol200910550851519410195
   PubMed Web of Science ®Google Scholar
• HiltonDARisticNHanemannCOActivation of ERK, AKT and JNK signalling pathways in human schwannomas in situHistopathology200955674474919919586
   PubMed Web of Science ®Google Scholar
• WeeSJaganiZXiangKXPI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancersCancer Res200969104286429319401449
   PubMed Web of Science ®Google Scholar
• JohannessenCMReczekEEJamesMFBremsHLegiusECichowskiKThe NF1 tumor suppressor critically regulates TSC2 and mTORProc Natl Acad Sci USA2005102248573857815937108
   PubMed Web of Science ®Google Scholar
• DucimetiereFLurkinARanchere-VinceDIncidence of sarcoma histotypes and molecular subtypes in a prospective epidemiological study with central pathology review and molecular testingPloS One201168e2029421826194
   PubMed Web of Science ®Google Scholar
• HernandoECharytonowiczEDudasMEThe AKT-mTOR pathway plays a critical role in the development of leiomyosarcomasNat Med200713674875317496901
   PubMed Web of Science ®Google Scholar
• HensleyMLUpdate on gemcitabine and docetaxel combination therapy for primary and metastatic sarcomasCurr Opin Oncol201022435636120520541
   PubMed Web of Science ®Google Scholar
• YangJDuXChenKGenetic aberrations in soft tissue leiomyosarcomaCancer Lett200927511818649996
   PubMed Web of Science ®Google Scholar
• SetsuNYamamotoHKohashiKThe Akt/mammalian target of rapamycin pathway is activated and associated with adverse prognosis in soft tissue leiomyosarcomasCancer201211861637164821837670
   PubMed Web of Science ®Google Scholar
• MitaMMPoplinEBrittenCDPhase I/IIa trial of the mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) administered orally in patients with refractory or advanced malignancies and sarcomaAnn Oncol2012
   Web of Science ®Google Scholar
• ChawlaSPStaddonAPBakerLHPhase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomasJ Clin Oncol2012301788422067397
   PubMed Web of Science ®Google Scholar
• DemetriGDChawlaSPvon MehrenMEfficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedulesJ Clin Oncol200927254188419619652065
   PubMed Web of Science ®Google Scholar
• SanfilippoRGrossoFJonesRLTrabectedin in advanced uterine leiomyosarcomas: a retrospective case series analysis from two reference centersGynecol Oncol2011123355355621917307
   PubMed Web of Science ®Google Scholar
• MonkBJBlessingJAStreetDGMullerCYBurkeJJHensleyMLA phase II evaluation of trabectedin in the treatment of advanced, persistent, or recurrent uterine leiomyosarcoma: a gynecologic oncology group studyGynecol Oncol20121241485221996263
   PubMed Web of Science ®Google Scholar
• SchoffskiPRay-CoquardILCioffiAActivity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2 study in four independent histological subtypesLancet Oncol201112111045105221937277
   PubMed Web of Science ®Google Scholar
• ItalianoAToulmondeMCioffiAAdvanced well- differentiated/dedifferentiated liposarcomas: role of chemotherapy and survivalAnn Oncol20122361601160722039081
   PubMed Web of Science ®Google Scholar
• AsanoNSusaMHosakaSMetastatic patterns of myxoid/round cell liposarcoma: a review of a 25-year experienceSarcoma2012201234516122550416
   PubMedGoogle Scholar
• HaniballJSumathiVPKindblomLGPrognostic factors and metastatic patterns in primary myxoid/round-cell liposarcomaSarcoma2011201153808522190864
   PubMedGoogle Scholar
• SleijferSOualiMvan GlabbekeMPrognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG)Eur J Cancer2010461728319853437
   PubMed Web of Science ®Google Scholar
• GronchiABuiBNBonvalotSPhase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcomaAnn Oncol201223377177621642514
   PubMed Web of Science ®Google Scholar
• GrossoFSanfilippoRVirdisETrabectedin in myxoid liposarcomas (MLS): a long-term analysis of a single-institution seriesAnn Oncol20092081439144419465423
   PubMed Web of Science ®Google Scholar
• GrossoFJonesRLDemetriGDEfficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective studyLancet Oncol20078759560217586092
   PubMed Web of Science ®Google Scholar
• MahmoodSTAgrestaSVigilCPhase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on 3 prevalent histologies: Leiomyosarcoma, liposarcoma, and malignant fibrous histiocytomaInt J Cancer201112981963196921154746
   PubMed Web of Science ®Google Scholar